What is the glomerular filtration rate (GFR) cutoff for using lisinopril (angiotensin-converting enzyme inhibitor) in patients with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lisinopril GFR Cutoff for Dosing

Lisinopril requires dose reduction when creatinine clearance (CrCl) or GFR falls below 30 mL/min/1.73 m², and should be initiated at half the usual dose (5 mg for hypertension, 2.5 mg for heart failure) in patients with CrCl 10-30 mL/min/1.73 m². 1

Specific Dosing Thresholds by Renal Function

GFR >30 mL/min/1.73 m²

  • No dose adjustment required 1
  • Standard initial dosing applies: 10 mg daily for hypertension, 5 mg daily for heart failure 1
  • Pediatric patients require GFR >30 mL/min/1.73 m² for lisinopril use 1

GFR 10-30 mL/min/1.73 m² (Stage 4 CKD)

  • Reduce initial dose to 50% of usual recommended dose: 1
    • Hypertension: Start at 5 mg daily (instead of 10 mg)
    • Heart failure: Start at 2.5 mg daily (instead of 5 mg)
    • Acute MI: Start at 2.5 mg daily (instead of 5 mg)
  • Can titrate up to maximum of 40 mg daily as tolerated 1
  • Drug accumulation occurs at this level of renal impairment 2, 3

GFR <10 mL/min/1.73 m² or Hemodialysis

  • Initial dose: 2.5 mg once daily 1
  • Lisinopril can be removed by hemodialysis 1
  • Significant drug accumulation expected 2

Critical Monitoring Requirements

When initiating or using lisinopril in patients with GFR <60 mL/min/1.73 m² (CKD Stage 3a-5), the following monitoring is essential: 4

  • Assess GFR and serum potassium within 1 week of starting therapy or any dose escalation 4
  • Monitor for hyperkalemia development 4
  • Do not routinely discontinue lisinopril in patients with GFR <30 mL/min/1.73 m² as ACE inhibitors remain nephroprotective 4

Temporary Discontinuation Scenarios

Temporarily suspend lisinopril during: 4

  • Serious intercurrent illness that increases AKI risk
  • Planned IV radiocontrast administration
  • Bowel preparation prior to colonoscopy
  • Prior to major surgery
  • Volume depletion states

Clinical Evidence in Renal Impairment

The safety and efficacy of lisinopril in renal impairment has been well-established in clinical studies:

  • Effective blood pressure control achieved in patients with GFR ≤60 mL/min using median doses of 10 mg daily 5, 6
  • Renal function remained stable during treatment, with mean GFR unchanged after 12 weeks (36-39 mL/min baseline vs. follow-up) 5, 3
  • Starting doses of 2.5 mg in patients with GFR <30 mL/min and 5 mg in those with GFR 30-60 mL/min were well-tolerated 6, 3
  • Only 13-17% of patients required addition of diuretic therapy 5, 6

Common Pitfalls to Avoid

Do not discontinue ACE inhibitors for creatinine increases ≤30% in the absence of volume depletion 4

Avoid starting lisinopril in suspected bilateral renal artery stenosis or functional renal artery stenosis 4

Do not use lisinopril in pediatric patients <6 years or with GFR <30 mL/min/1.73 m² as safety and efficacy have not been established in these populations 1

Monitor more frequently in severe renal impairment (GFR <30 mL/min/1.73 m²) as overlooking the need for closer monitoring can lead to adverse outcomes including hyperkalemia and worsening renal function 7

References

Research

The clinical pharmacology of lisinopril.

Journal of cardiovascular pharmacology, 1987

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lisinopril in hypertension associated with renal impairment.

Journal of cardiovascular pharmacology, 1987

Guideline

Methylprednisolone Use in Patients with Severe Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.